drugset / Trial / NCT03631420

Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants

NCT03631420

Phase 1 Recruiting 9 enrolled Meridigen Biotech Co., Ltd.
NaSingle-groupOpen-labelPrevention

Summary

The clinical study with UMC119-01 is designed to investigate the safety in patients with bronchopulmonary dysplasia ("BPD"). This will be a dose escalation, open-label, single-center study in infants at high risk for BPD.

Timeline

Start
2018-10-26
Primary completion
2025-12-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 3 cells/kg
Subject human umbilical cord mesenchymal stem cells Cell therapy 10 cells/kg
Subject human umbilical cord mesenchymal stem cells Cell therapy 30 cells/kg